Sentence examples for microarray platforms have from inspiring English sources

In recent years, genome-wide screening of copy number alterations by comparative genomic hybridization and genomic microarray platforms have revealed a characteristic MCL profile of multiple secondary gains and losses as well as regions of copy number neutral loss of heterozygosity that target mainly genes involved in cell cycle regulation, DNA damage response, and cell survival pathways.

These rice microarray platforms have been successfully used in characterizing gene expression profiles from different tissues and organs (Wang et al.[2010]), different cell types (Jiao et al.[2009]), under biotic and abiotic treatment conditions (Jung et al.[2008b]; Swarbrick et al.[2008]; Jung et al.[2010]), identification of alternative splice (Jung et al.[2009]) and mutants (Bruce et al.[2009]).[2009]

Many commonly-used, commercially available microarray platforms have been refined to the point that most of the probes used have similar, and close to idealized, hybridization properties [28], [29], [30].

Multiplexed immunoassays based on protein microarray platforms have been broadly employed in the discovery and validation of disease-associated biomarkers as well as in clinical diagnostics research [20] [25].

As listed below, three whole-genome oligo microarray platforms have been developed for rice based on early rice gene predictions (called pseudomolecules) from The Institute for Genomic Research TIGRR) and/or rice full-length cDNAs available from the Knowledge-based Oryza Molecular biological Encyclopedia (KOME, http://cdna01.dna.affrc.go.jp/cDNA/) [23].

Recently, its advantages over microarray platforms have been described by many comparative reports [ 16].

However, no comparative and quality control study of microRNA microarray platforms has been reported yet.

The diversity of microarray platforms has made it a challenge to re-use and/or integrate datasets generated in different experiments to construct array-based diagnostic models.

The large number of commercially available microarray platforms has expanded the use of the technology and made it more widely available to different laboratories.

The development and marketing of microarray platforms has led to extensive investigation of global gene expression profiles in health and disease.

The advent of oligonucleotide-based microarray platforms has facilitated the development of several clinically useful gene expression signatures, which offer the promise of incorporating genomic features other than ER, PR, and HER2 into clinical management of breast cancer patients.